Compositions and methods for the augmentation and repair of defects in tissue

• US 20070065415A1
• Filed: 09/16/2005
• Published: 03/22/2007
• Est. Priority Date: 09/16/2005
• Status: Abandoned Application

• Current Assignee: DASK Technologies LLC
• Original Assignee: DASK Technologies LLC
• Inventors: Soto, Adriana, Kleinsek, Donald
• Application Number:
  US11/229,237
• Publication Number:
  US 20070065415A1
• Time in Patent Office: Days
• US Class Current: 424/93.700
• CPC Class Codes: A61K 35/12 Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells vaccines or medicinal preparations containing antigens or antibodies A61K39/00
• CPC Class Codes: A61K 35/33 Fibroblasts
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00

Abstract

Compositions and methods of treating a defect in a patient are disclosed, including expanding a culture of autologous cells in vitro to form cultured cells, collecting the cultured cells for introduction into the patient, and depositing the cultured cells with ancillary proteins.

Claims

1. A composition comprising an in vitro preparation of autologous cells and an immunogenic cell-absorbable protein immunogenic relative to an individual that contributed the autologous cells.

2. The composition of claim 1, wherein the protein is:

a recombinant protein, a soluble protein, an insoluble protein, an extracellular matrix molecule a serum protein, a growth factor, a hormone, a cytokine, a chemokine or a cell adhesion protein.

3. The composition of claim 1, wherein the protein is non-autologous.

4. The composition of claim 1, wherein the protein is used during the culture of the cells or is added to the cells after culturing of the cells is completed.

5. The composition of claim 1, wherein the protein contains a cell binding site or contains an ECM binding site.

6. The composition of claim 1, wherein the protein is a proteoglycan, fibronectin, vitronectin, chondronectin, laminin, tenascin, fibrinogen, fibrin, fibulin, von Willebrand'"'"'s factor, aggrecan, or elastin.

7. The composition of claim 1, further comprising a protein that provides additional elasticity to the tissue.

8. The composition of claim 1, wherein the protein that provides additional elasticity to the tissue.

9. The composition of claim 1, wherein the protein is a proteoglycan chosen from the group consisting of, agrin, bamacan, brain enriched hyaluronan, biglycan, brevican, decorin, fibromodulin, keratocan, lumican, neurocan, perlecan, syndecan, heparan sulfate proteoglycan, and versican.

10. The composition of claim 1, further comprising an apoptosis inhibiting protein, an anoikis inhibiting protein, a protease inhibiting factor, a transport protein, a procoagulation protein, a cell mitogen, a differentiation protein, a filler or augmenting protein, a pro-inflammatory protein, a vasodilator protein, an angiogenesis protein, a chemoattractant, a vasodilator, a promoter of ECM production, a cell proliferation protein, a differentiation protein, or a cell culture medium serum-derived protein.

11. The composition of claim 1, wherein the protein is an apoptosis inhibiting protein, an anoikis inhibiting protein, an angiogenesis protein, a vasodilator protein, a pro-inflammatory protein, a filler or augmenting protein, a differentiation protein, a cell mitogen, a promoter of extracellular matrix production, a chemoattractant, a cell culture medium serum-derived protein, a procoagulation protein, a transport protein, or a protease inhibiting factor.

12. The composition of claim 1, wherein the autologous cells are chosen from the group consisting of papillary fibroblasts, reticular fibroblasts, fascia fibroblasts, preadipocytes, and adipocytes.

13. The composition of claim 1, wherein the autologous cells comprise denial fibroblasts.

14. The composition of claim 1, wherein the autologous cells comprise lamina propria fibroblasts, stromal fibroblasts, myofibroblasts, derma papilla fibroblasts, muscle cells, smooth muscle cells, skeletal muscle cells, striated muscle cells, myoblasts, epithelial cells, endothelial cells or epidermal cells.

15. The composition of claim 1, wherein the autologous cells comprise mesenchymal cells, nondifferentiated mesenchymal cells, or stem cells.

16. A method of treating a defect in a patient comprising:

expanding a culture of autologous cells in vitro to form cultured cells, collecting the cultured cells for introduction into the patient, and depositing the cultured cells with a serum-derived protein at or near the defect in the patient.

17. The method of claim 16, wherein the protein is present as a component of serum.

18. The method of claim 16, wherein the serum-derived protein has not been previously exposed to the cells.

19. The method of claim 16, wherein the serum-derived protein bas been previously used in culture medium used to culture the cells and was thereby exposed to the cultured cells.

20. The method of claim 16, wherein the protein is found in serum and is produced by recombinant techniques.

21. The method of claim 16, wherein the protein is an immunogenic protein.

22. The method of claim 16, wherein the protein is present at a concentration of more than 0.1% v/v or a concentration of more than 0.1% w/w relative to the concentration of the protein in a cell culture medium last used to culture the cultured cells.

23. The method of claim 16, wherein the protein is a soluble proteins an insoluble protein, in a gel, an extracellular matrix molecule, a serum protein, a growth factor, a hormone, a cytokine, or a cell adhesion protein.

24. The method of claim 16, wherein the protein is non-autologous.

25. The method of claim 16, wherein the protein contains a cell binding site or contains an ECM binding site.

26. The method of claim 16, wherein the protein is a proteoglycan, fibronectin, vitronectin, chondronectin, laminin, tenascin, fibrinogen, fibrin, fibulin, von Willebrand'"'"'s factor, aggrecan, or elastin.

27. The method of claim 16, further comprising mixing a protein that provides additional elasticity to the tissue with the cells and the serum-derived protein.

28. The method of claim 16, wherein the protein provides additional elasticity to the tissue.

29. The method of claim 16, wherein the defect is chosen from the group consisting of a rhytid, stretch mark, depressed scar, cutaneous depression, hypoplasia of the lip, wrinkle, prominent nasolabial fold, prominent melolabial fold, and scarring from acne vulgaris.

30. The method of claim 16, wherein the defect is chosen from the group consisting of skin laxness, skin thinning, hypertrophic scars, wound, burn, hernia, breast deficiency, ligament tear, tendon tear, muscle tear, baldness, a periodontal disorder, a periodontal disease, and sphincter structure deficiency.

31. The method of claim 16, wherein the protein is a proteoglycan chosen from the group consisting of, agrin, bamacan, brain enriched hyaluronan, biglycan, brevican, decorin, fibromodulin, keratocan, lumican, neurocan, perlecan, syndecan, heparan sulfate proteoglycan and versican.

32. The method of claim 16, further comprising, in a mixture with the serum-derived protein and the cultured cells, a protein that is an apoptosis inhibiting protein, and anoikis inhibiting protein, an angiogenesis protein, a vasodilator protein, a pro-inflammatory protein, a filler or augmenting protein, a differentiation protein, a cell mitogen, a promoter of extracellular matrix production, a chemoattractant, a cell culture medium serum-derived protein, a procoagulation protein, a transport protein, or a protease inhibiting factor.

33. The method of claim 16, wherein the protein is an apoptosis inhibiting protein, and anoikis inhibiting protein, an angiogenesis protein, a vasodilator protein, a pro-inflammatory protein, a filler or augmenting protein, a differentiation protein, a cell mitogen, a promoter of extracellular matrix production, a chemoattractant, a cell culture medium serum-derived protein, a procoagulation protein, a transport protein, or a protease inhibiting factor.

34. The method of claim 16, wherein the autologous cells comprise papillary fibroblasts, reticular fibroblasts, fascia fibroblasts, preadipocytes, or adipocytes.

35. The method of claim 16, wherein the autologous cells comprise lamina propria fibroblasts, stromal fibroblasts, myofibroblasts, derma papilla fibroblasts, muscle cells, smooth muscle cells, skeletal muscle cells, striated muscle cells, myoblasts, epithelial cells, or epidermal cells.

36. The method of claim 16, wherein the autologous cells comprise mesenchymal cells, nondifferentiated mesenchymal cells, or stem cells.

37. A method of treating a defect in a patient comprising:

expanding a culture of autologous cells in vitro, collecting the cells for introduction into the patient, incubating the cells with an effective amount of an immunogenic cell-absorbable protein, and depositing the cells at or near the defect in the patient to repair or augment a tissue at or near the defect.

38. The method of claim 37, wherein the protein is:

a recombinant protein, a soluble protein, an insoluble protein, an extracellular matrix molecule a serum protein, a growth factor, a hormone, a cytokine, a chemokine or a cell adhesion protein.

39. The method of claim 37, wherein the protein is non-autologous.

40. The method of claim 37, wherein the protein is used during the culture of the cells or is added to the cells after culturing of the cells is completed.

41. The method of claim 37, wherein the protein contains a cell binding site or contains an ECM binding site.

42. The method of claim 37, wherein the protein is a proteoglycan, fibronectin, vitronectin, chondronectin, laminin, tenascin, fibrinogen, fibrin, fibulin, von Willebrand'"'"'s factor, aggrecan, or elastin.

43. The method of claim 37, further comprising a protein that provides additional elasticity to the tissue.

44. The method of claim 37, wherein the protein provides additional elasticity to the tissue.

45. The method of claim 37, wherein the protein is a proteoglycan chosen from the group consisting of, agrin, bamacan, brain enriched hyaluronan, biglycan, brevican, decorin, fibromodulin, keratocan, lumican, neurocan, perlecan, syndecan, heparan sulfate proteoglycan, and versican.

46. The method of claim 37, further comprising an apoptosis inhibiting protein, an anoikis inhabiting protein, a protease inhibiting factor, a transport protein, a procoagulation protein, a cell mitogen, a differentiation protein, a filler or augmenting protein, a pro-inflammatory protein, a vasodilator protein, an angiogenesis protein, a chemoattractant, a vasodilator, a promoter of ECM production, a cell proliferation protein, a differentiation protein, or a cell culture medium serum-derived protein.

47. The method of claim 37, wherein the protein is an apoptosis inhibiting protein, an anoikis inhibiting protein, an angiogenesis protein, a vasodilator protein, a pro-inflammatory protein, a filler or augmenting protein, a differentiation protein, a cell mitogen, a promoter of extracellular matrix production, a chemoattractant, a cell culture medium serum-derived protein, a procoagulation protein, a transport protein, or a protease inhibiting factor.

48. The method of claim 37, wherein the autologous cells are chosen from the group consisting of papillary fibroblasts, reticular fibroblasts, fascia fibroblasts, preadipocytes, and adipocytes.

49. The method of claim 37, wherein the autologous cells comprise dermal fibroblasts.

50. The method of claim 37, wherein the autologous cells comprise lamina propria fibroblasts, stromal fibroblasts, myofibroblasts, derma papilla fibroblasts, muscle cells, smooth muscle cells, skeletal muscle cells, striated muscle cells, myoblasts, epithelial cells, endothelial cells or epidermal cells.

51. The method of claim 37, wherein the autologous cells comprise mesenchymal cells, nondifferentiated mesenchymal cells, or stem cells.